X-Chromosome Inactivation and Related Diseases

Zhuo Sun, Jinbo Fan, and Yang Wang

1. Xi’an Key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi’an Medical University, No. 1 XinWang Road, Weiyang District, Xi’an 710021, Shaanxi, China
2. Institute of Basic Medical Sciences, Xi’an Medical University, No. 1 XinWang Road, Weiyang District, Xi’an 710021, Shaanxi, China

Correspondence should be addressed to Yang Wang; yang.wang@xiyi.edu.cn

Received 8 October 2021; Revised 2 February 2022; Accepted 17 March 2022; Published 27 March 2022

X-chromosome inactivation (XCI) is the form of dosage compensation in mammalian female cells to balance X-linked gene expression levels of the two sexes. Many diseases are related to XCI due to inactivation escape and skewing, and the symptoms and severity of these diseases also largely depend on the status of XCI. Here, we review representative diseases in terms of their definition, symptoms, and XCI’s role in the pathogenesis of these diseases.

1. X-Chromosome Inactivation, Escape, and Skewing

During XCI, many epigenetic events take place and ensure the compacted heterochromatin structure of the inactive X chromosome (X inactive, Xi) to silence most genes on the chromosome. XIST lncRNA is expressed and coats the Xi in cis [1, 2], which starts a cascade of events including substitution of macroH2A [3], the removal of active histone modifications [4, 5], the addition of repressive histone modifications [6–9], CpG islands methylation [10], and heterochromatin protein recruitment [11, 12]. As a result, the Xi is compacted into a rounder shape compared to the more flat structure of the active X chromosome (X active, Xa) [13].

Not all genes on the Xi are in a repressed state. It is estimated that about 15%–30% of all the genes on the Xi escape gene repression and are expressed [14, 15]. For different individuals, ages, and cell types, the gene escape patterns are diverse [14, 16]. Some genes are found to be escaping in most cell types, others are highly variable depending on the origin of cells. The occurrence of escaped genes has been found to be essential in the pathogenesis of many diseases including autoimmune diseases [17] and cancer [18–21].

Skewed X-chromosome inactivation or X-chromosome inactivation skewing describes the phenomenon when more than 75% of cells in an individual chose the X chromosome from one parent as the Xi. This occurs since the choice of which X chromosome to silence is random and it takes place early in the gastrulation stage, so when the choice is at the tail end of the normal distribution, or if alleles of specific genes from one parent’s origin render the cells more robust, it may lead to skewing of the X-chromosome inactivation, instead of the 50% completely random choice [22, 23]. It is estimated that 1.5%–23% of females have skewed X inactivation [24–26]. The direction and degree of XCI skewing may influence the severity of some diseases including haemophilia B [27, 28], dyskeratosis congenita [29], Duchenne muscular dystrophy [30], myotubular myopathy [31], and Fabry disease (FD) [32, 33], which will be discussed more in detail in this review.

Many diseases have been found to be related to the XCI process. They can be roughly categorized to 3 types: (1) X-linked gene diseases, whose severity is greatly influenced by the direction and degree of X-inactivation skewing; here, we review FD that can be categorized to this type; (2) diseases that have higher occurrence in female population due to the presence of an extra pair of X chromosome and...
the possibilities to have escaped gene expression from the Xi: systemic lupus erythematosus (SLE) will be reviewed in this paper as an example; (3) X-chromosome aneuploidy: Turner syndrome (TS, 45), triple X syndrome (47, XXX), and Klinefelter syndrome (47, XXY) belong to this type. These diseases will be reviewed in terms of their clinical symptoms, pathogenic mechanism, and the role of XCI in the clinical presentation.

2. XCI-Related Diseases

2.1. X-Linked Diseases. For almost all X-linked diseases, clinical manifestation is more severe in males than in females. Female carriers are either asymptomatic or show milder phenotypes compared to males. Sex differences in these X-linked diseases are due to XCI [34]. Males are hemizygous for most X-linked genes; thus, a male carrier of a mutant allele is usually affected with full presentation of the disease clinical features. Females have two types of cells in terms of their XCI status: those whose maternal X is active and those whose paternal X is active. Therefore, even if a female carries one copy of mutant allele, she probably still does not have full clinical presentation because a portion of the female cells has the mutant X inactivated. Data from OMIM show that there are more than 500 X-linked diseases that affect males more severely. X-linked retinitis pigmentosa [35, 36], Duchenne muscular dystrophy [37], FD, and fragile X syndrome all belong to this category.

Among those X-linked diseases with higher male susceptibility, some rarely affect females, whereas others can present severe symptoms in female heterozygotes. There are mainly two factors behind whether female heterozygotes will have clinical manifestation: protein transfer and cell selection [38]. Protein transfer is the process when variant cells could not make functional proteins but wildtype cells can transfer functional proteins into those deficient cells to make up for the loss. Cell selection is the process when there is a growth advantage for either the wildtype cells or mutant cells because of the mutant phenotype, the other cell population dies off gradually, making disease manifestation not evident or very severe, respectively.

Hunter syndrome and FD are both X-linked lysosomal enzyme diseases. Hunter syndrome rarely affects females [39], whereas FD can present severe symptoms in female patients. The difference in female susceptibility lies in the different ability for cells to share the lysosomal enzyme [40]. The enzyme iduronic sulfate loss in Hunter syndrome can be readily supplied by nearby wildtype cells, whereas the mature form of α-galactosidase A (α-GAL A) is hard to uptake for mutant cells in FD [41].

There are X-linked diseases that only or mainly affect females. Those disease variants usually cause loss of an essential protein completely, so that males are lethal in utero, leaving females to be the major sex to be afflicted with these diseases. Cornelia de Lange 2 (with SMC1A truncating variants) [42] and CHILD syndrome [43] only affect females since male carriers are lethal in utero. Other diseases affect some males due to a milder form of mutant or mosaic. Rett syndrome [44], incontinentia pigmenti type 2 [45], and focal dermal hypoplasia [46] all belong to this type.

In the next part, FD will be discussed in detail as an example to show how XCI is involved in the pathogenesis of X-linked diseases. FD is caused by mutations in the GLA gene which codes for the α-GAL A enzyme. α-GAL A breaks down globotriaosylceramide and glycosphingolipids in the lysosome for recycling in cell metabolism, and decreased activity or loss of α-GAL A leads to buildup of those molecules in the lysosome which can cause multisystemic effects in patients [47]. α-GAL A is abundant in the kidney and vascular tissues, and key manifestation of FD includes malfunction of the kidney and heart. The estimated incidence of FD is 1 in 117,000 [48].

The disease phenotype depends on residual enzyme activity: less than 1% of normal activity results in classic FD, and levels between 1% and 30% leads to atypical forms of FD (also called late-onset FD). Classic FD mainly affects males. Classic FD patients usually present symptoms early in childhood that include acute pain in extremities and fatigue, hypohidrosis [49], neuropathic pain in the hands and feet, angiokeratomas in the lower abdomen and bathing trunk area [50], gastrointestinal problems, and cornea verticillata [51, 52]. Because of the residual α-GAL A activity, atypical FD patients develop symptoms much later in life. Some develop multiple symptoms as young adults, while others only show signs of FD in specific organs such as the heart and kidneys. Heterozygous females have 0–100% of normal plasma α-GAL A activity and can have symptoms that range from mild to severe depending on their skewing of XCI [53].

Males are usually severely affected, whereas clinical presentation in female patients is more variable [53, 54]. Females usually develop symptoms in their adulthood which is much later than males, and symptoms are usually milder [55]. This can lead to misdiagnosis in female patients. Since male has one copy of X chromosome, defect in the GLA gene can cause FD in males, whereas female has two X chromosomes and depending on X chromosome being inactivated and skewing of XCI, female mutant gene carriers can have a spectrum of clinical presentation from completely nonsymptomatic to severe symptoms as seen in males [56].

In female FD patients, both random XCI and skewed XCI are observed. In a study that evaluated XCI pattern of four different tissues from female FD patients, random XCI is observed in 71% of samples and skewed XCI in 29% of samples [56]. Other studies have found similar ratios [33, 57]. For patients with random XCI, disease presentation usually worsens severely with age, which is partially due to inefficient protein transfer between wildtype and affected cells. For patients with skewed XCI, predominant expression of the mutant GLA allele usually results in early onset and rapid progression in FD, whereas the favored expression of the wildtype GLA allele is associated with mild phenotype and little progression over time.

For male patients, diagnosis can be confirmed by low α-GAL A activity in leukocytes, whereas for female patients, α-GAL A activity can range from very low to normal levels. Therefore, gene sequencing is the gold standard for diagnosis in females [58]. It has been shown that level of α-GAL A
cannot predict the severity of symptoms well in female patients, and some researchers argue that the enzyme deficiency may result in other pathogenetic mechanisms [59–61].

It was believed that skewed XCI is the main reason for phenotype variability in female heterozygotes [32, 33, 56, 62], but recently some studies have come at the conclusions that skewed XCI could not explain all cases of severe FD and is not the main factor in the variable clinical presentation of FD in females [57, 63, 64].

One factor that might have complicated the results is the tissues chosen for analyzing the XCI skewing. Most studies chose easily accessible leukocytes, urinary cells, and buccal epithelia, rather than the tissues from affected organs, such as cardiac and renal tissues. Also, XCI skewing pattern could be different in different tissues from the same subject [65]. Examining samples from affected tissues would give the best perspective on XCI skewing’s role in phenotype variability in female patients, but would require invasive biopsies.

Since some female patients with severe symptoms have random XCI, it points to factors other than XCI skewing that contribute to FD disease severity in heterozygous females. The nature of mutation could be essential in determining disease severity. Mutations that result in complete loss of the functional protein result in severe phenotypes, whereas missense mutations could result in mild phenotype or late-onset presentation. Even for family members with the same mutation, there could be vastly different clinical expression [61, 66]. It is likely that besides XCI skewing and nature of mutation, the variability in female patients is dependent on other genetic, epigenetic, and environment factors as well [58].

2.2. Diseases That Are Affected by XCI Escape or X-Chromosome Dosage Effect. Another type of diseases that are affected by XCI are due to X-inactivation escape. The escape and thus overexpression of some genes in female cells could be related to disease presentation and sex bias in those diseases. These include autoimmune diseases (SLE and autoimmune thyroid diseases [67, 68]) and some psychiatric disorders (bipolar disorder and major depression [69]).

Here, SLE will be discussed in detail as an example to show how XCI is involved in the pathogenesis of diseases affected by XCI escape and X-chromosome dosage effect. Many autoimmune diseases have sex bias where number of female patients is significantly higher than that of male patients. Many factors contribute to the sex bias including difference in innate immunity, immune response intensity [70], and hormones [71]. Many genetic risk loci have been discovered to be associated with SLE predisposition, some of which are X-linked. The extra pair of X chromosome, the possibility for these genes to escape, and a higher amount of the gene product in females than males contribute to sex bias of this disease.

SLE is a chronic autoimmune disease which leads to variable clinical presentations depending on the major organ affected. The word erythematous refers to the rash that patients usually have on their skin. SLE incidence ranges from 2.2 to 23.1/100,000 person-years globally [72, 73], with the highest estimated incidence in North America. Women have higher prevalence of SLE [74, 75], and people of African ethnicity have higher incidence and prevalence than Caucasians [76].

For people with predisposition for SLE, antinuclear antibodies are produced and form immune complexes with nuclear antigen, which then deposit in tissues and cause inflammation. Antibodies against red blood cells and white blood cells could also be produced and result in type II hypersensitivity. There are more than 80 genetic predispositions that have been discovered to date, such as TREX1 [77], C8orf13-BLK [78], ITGAM-ITGAX [78], IL10 [79], TNIP1 [79], and IKZF1 [80] (the abovementioned gene loci are not X-linked). For most patients, SLE is caused by mutations in several genes rather than a single locus.

Besides genetic factors, there are also epigenetic factors that are essential in the disease pathogenesis. There is around 70%–75% discordance of SLE incidence between identical twins [81, 82]; this could be due to the different epigenetic landscapes for these twins and also different X-inactivation pattern [83]. X-linked genes that are related to onset of SLE might be differentially inactivated among different cells, tissues, and individuals, contributing to the different onset of SLE in identical twins [84].

Symptoms of SLE include fatigue, fever, painful joints, rashes (especially butterfly-shaped rash on the cheek), and sensitivity to sun [85]. Since there are a variety of general and specific symptoms, diagnosis of SLE is difficult. Patients are diagnosed by adding scores from 10 clinical domains: constitutional, cutaneous, arthritis, neurological, serositis, haematological, renal, antiphospholipid antibodies, complement proteins, and highly specific antibodies [86]. SLE is characterized by periods of flare-ups and remittance, and treatments mainly involve immunomodulation and immunosuppression drugs and are targeted at preventing and limiting the severity of flare-ups.

Ratio of women with SLE to men is estimated to be 9:1 to 11:1. There could be several factors that contribute to the gender difference in disease susceptibility. These factors are hormones [87, 88], X-chromosome dosage factor, and X-linked gene overexpression.

It is shown that sex steroids can regulate autoimmune regulator (AIRE) locus expression, which in turn affects susceptibility to autoimmune diseases [89, 90]. The fact that there is big increase of SLE incidence and prevalence in postpubertal females than males and prepubertal females also implies that sex hormones play an important role in the onset of SLE [91, 92].

The hypothesis that X-chromosome dosage is a contributing factor in SLE sex bias comes from the observations of SLE incidence in X-chromosome aneuploidies. Women with TS (45, X) are underrepresented compared to karyotypically normal women (46, XX) in SLE [93]. The risk of SLE in Klinefelter syndrome (47, XXY) males is 14-fold higher than karyotypically normal men (46, XY) [94]. The estimated prevalence of SLE in women with (47, XXY) is 2.5 times higher than women with normal karyotype and is 25 times higher than men [95], suggesting that dosage of X
chromosome could be related to disease pathogenesis. Evidence from mouse models also indicates that an extra X chromosome is an important contributing factor in female bias in autoimmunity [96, 97]. It is important to note that chromosome dosage factor could be in part due to X-linked gene escape [98], which is the factor that is discussed next.

Overexpression of several X-linked genes has been shown to be involved in SLE pathogenesis, such as CD40LG [99], CXCR3 [100], KDM6A [101], CXorf21 [98], MECP2 [102, 103], IRAK1 [75, 103], TLR7 (Toll-like receptor 7) [104, 105], GPR173 [106], and PRPS2. Several of them are immunity genes, including CD40LG, CXCR3, CXorf21, IRAK1, and TLR7. There could be 3 different scenarios of these X-linked gene overexpression, whether transcription from the active X allele is enhanced or there is escape from the inactive X allele or both. For the scenarios where XCI escape is involved in overexpression, it contributes to sex bias. Females by having the extra X chromosome have chances of XCI escape, whereas males do not.

Several studies have looked at the overexpression origin. TLR7 binds RNA in endosomes and activates the interferon response. TLR7 overexpression is observed in male patients, which is due to a SNP that increased transcription of the gene on the active X chromosome [104]. Another study found that there is biallactic expression of TLR7 in both female normal and SLE patient B cell lines, which means TLR7 is an escape even in healthy individuals [17]. The abovementioned studies show that TLR7 overexpression can come from both enhancing Xa allele expression and escape from Xi. CXorf21 is another immunity-related gene that shows XCI escape and has female-biased expression [98]. These are two examples of X-linked immunity gene escape contributing to sex bias in SLE.

A few other of these X-linked genes show overexpression only in female SLE patients but not in males, such as CD40LG [107, 108] and CXCR3 [108], which means the overexpression comes from the Xi, rather than Xa. Demethylation of the promoter region is also observed, which suggests that overexpression originates from XCI escape.

It has recently been observed that inactive X chromosome in SLE patient B cells have dramatic reduction in heterochromatic modifications, predisposing X-linked immunity gene escape [109]. This has provided further mechanistic insight as to how X-linked genes might contribute to SLE pathogenesis and sex bias.

2.3. X-Chromosome Aneuploidy. X-chromosome aneuploidy results in disease phenotypes in human: TS (45, X), Klinefelter syndrome (47, XXY), and triple X syndrome (47, XXX). For both Klinefelter syndrome and triple X syndrome, only one X chromosome remains active and all extra pairs of X chromosomes are inactivated. It is hypothesized that overexpression of escape genes results in the phenotypic abnormalities seen in those diseases [110]. The expression would be lower in TS due to haploinsufficiency. Indeed, SHOX gene, which escapes XCI, has been associated with tall stature in Klinefelter syndrome and triple X syndrome and short stature in TS [111, 112]. On the other hand, increased expression is also observed for some X-linked genes with decreasing X-chromosome dosage [113], indicating a compensatory mechanism in the complex relationship between X-chromosome dosage and X-linked gene expression level.

There is complex and diverse comorbidity associated with X-chromosome aneuploidy diseases, and identifying causal genes for different phenotypes has been difficult [114]. However, recent studies of genome-wide DNA methylation profile and transcriptome in patients revealed that there is DNA hypermethylation associated with Klinefelter syndrome and DNA hypomethylation associated with TS, which also shed light upon several candidate genes [114, 115].

3. Future Directions

X-linked diseases affect female patients differently resulting in a wide range of phenotype depending on their X-chromosome inactivation pattern. As seen in the review above, most of the studies mentioned are case studies and larger sample size could benefit exploration of the relationship between skewed X inactivation and phenotype severity. It is also important to note the cell type used when analyzing XCI skewing pattern, since it varies between different cell types even in the same individual. Also, it would be the best to analyze samples from affected organs to explore the relationship between XCI skewing and phenotype severity in female heterozygotes. Targeted reactivation of normal allele on the Xi could be further explored to support the development of more treatment options, as shown in studies in rodent models and cell lines [116, 117].

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

This work was supported by the PhD starting fund from Xi'an Medical University (no. 2020DOC14), funding from the Innovative Group of Xi'an Medical University (no. 2021TD01), Natural Science Basic Research Plan in Shaanxi Province of China (no. 2021Q-776), Specialized Research Fund of Department of Education in Shaanxi Province (nos. 21JK0896 and 21JK0886), and National Natural Science Foundation of China (no. 32070069).

References

[1] C. J. Brown, B. D. Hendrich, J. L. Rupert et al., “The human XIST gene: analysis of a 17 kb inactive X-specific RNA that contains conserved repeats and is highly localized within the nucleus,” Cell, vol. 71, no. 3, pp. 527–542, 1992.
[2] N. Brockdorff, A. Ashworth, G. F. Kay et al., “The product of the mouse Xist gene is a 15 kb inactive X-specific transcript containing no conserved ORF and located in the nucleus,” Cell, vol. 71, no. 3, pp. 515–526, 1992.
[3] C. Costanzi and J. R. Pehrson, “Histone macroH2A1 is concentrated in the inactive X chromosome of Female Mammals,” Nature, vol. 628, pp. 1997–1999, 1998.
[4] P. Jeppesen and B. M. Turner, “The inactive X chromosome in female mammals is distinguished by a lack of histone H4 acetylation, a cytogenetic marker for gene expression,” Cell, vol. 74, no. 2, pp. 281–289, 1993.

[5] B. P. Chadwick and H. F. Willard, “Cell cycle-dependent localization of macroH2A in chromatin of the inactive X chromosome,” Journal of Cell Biology, vol. 157, no. 7, pp. 1113–1123, 2002.

[6] B. A. Boggs, P. Cheung, E. Heard, D. L. Spector, A. C. Chinnault, and C. D. Allis, “Differentially methylated forms of histone H3 show unique association patterns with inactive human X chromosomes,” Nature Genetics, vol. 30, no. 1, pp. 73–76, 2002.

[7] A. H. F. M. Peters, J. E. Mermoud, D. O’Carroll et al., “Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin,” Nature Genetics, vol. 30, no. 1, pp. 77–80, 2002.

[8] K. Plath, J. Fang, S. K. Mlynarczyk-Evans et al., “Role of histone H3 lysine 27 methylation in X inactivation,” Science, vol. 300, no. 5616, pp. 131–135, 2003.

[9] J. Silva, W. Mak, I. Žvetkova et al., “Establishment of histone H3 methylation on the inactive X chromosome requires transient recruitment of Eed-Enxl polycromb group complexes,” Developmental Cell, vol. 4, no. 4, pp. 481–495, 2003.

[10] G. P. Pfeifer, R. L. Tanguay, S. D. Steigerwald, and C. D. Allis, “Differentially methylated forms of histone H3 show unique association patterns with inactive human X chromosomes,” Nature Genetics, vol. 30, no. 1, pp. 73–76, 2002.

[11] B. P. Chadwick and H. F. Willard, “Chromatin of the Barr body: histone and non-histone proteins associated with or excluded from the inactive X chromosome,” Human Molecular Genetics, vol. 12, no. 17, pp. 2167–2178, 2003.

[12] M. E. Blewitt, A.-V. Gendrel, Z. Pang et al., “SmcHD1, containing a structural-maintenance-of-chromosomes hing domain, has a critical role in X inactivation,” Nature Genetics, vol. 40, no. 5, pp. 663–669, 2008.

[13] K. Teller, D. Illner, S. Thamm et al., “A top-down analysis of Xa- and Xi-territories reveals differences of higher order structure at ≥20 Mb genomic length scales,” Nucleus, vol. 2, no. 5, pp. 465–477, 2011.

[14] L. Carrel and H. F. Willard, “X-inactivation profile reveals extensive variability in X-linked gene expression in females,” Nature, vol. 434, no. 7031, pp. 400–404, 2005.

[15] B. P. Balaton and C. J. Brown, “Escape artists of the X chromosome,” Trends in Genetics, vol. 32, no. 6, pp. 348–359, 2016.

[16] T. Tukiainen, A. C. Villani, A.-C. Villani et al., “Landscape of X chromosome inactivation across human tissues,” Nature, vol. 550, no. 7675, pp. 244–248, 2017.

[17] J. Wang, C. M. Syrett, M. C. Kramer, A. Basu, M. L. Atchison, and M. C. Anguera, “Unusual maintenance of X chromosome inactivation predisposes female lymphocytes for increased expression from the inactive X.” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 14, pp. E2029–E2038, 2016.

[18] G. J. Pageau, L. L. Hall, S. Ganesan, D. M. Livingston, and J. B. Lawrence, “The disappearing Barr body in breast and ovarian cancers,” Nature Reviews Cancer, vol. 7, no. 8, pp. 628–633, 2007.

[19] R. Chaligné, T. Popova, M.-A. Mendoza-Parras et al., “The inactive X chromosome is epigenetically unstable and transcriptionally labile in breast cancer,” Genome Research, vol. 25, no. 4, pp. 488–503, 2015.

[20] J. Kang, H. J. Lee, J. Kim, J. J. Lee, and L.-S. Maeng, “Dysregulation of X Chromosome inactivation in high grade ovarian serous adenocarcinoma,” PloS One, vol. 10, no. 3, Article ID e0118927, 2015.

[21] S. J. Winham, N. B. Larson, S. M. Armasu et al., “Molecular signatures of X chromosome inactivation and associations with clinical outcomes in epithelial ovarian cancer,” Human Molecular Genetics, vol. 28, 2019.

[22] J. W. Belmont, “Genetic control of X inactivation and X-linked mutations: unbalanced X inactivation is a powerful means to ascertain X-linked genes that affect cell proliferation,” The American Journal of Human Genetics, vol. 62, no. 6, pp. 1555–1557, 1998.

[23] A. Sharp, D. Robinson, and P. Jacobs, “Age- and tissue-specific variation of X chromosome inactivation ratios in normal women,” Human Genetics, vol. 107, no. 4, pp. 343–349, 2000.

[24] L. Busque, R. Mio, J. Mattioli et al., “Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age,” Blood, vol. 88, no. 1, pp. 59–65, 1996.

[25] M. C. Lanasa, W. A. Hogge, C. Cubik, J. Blancto, and E. P. Hoffman, “Highly skewed X-chromosome inactivation is associated with idiopathic recurrent spontaneous abortion,” American Journal of Human Genetics,vol. 65, no. 1, pp. 252–254, 1999.

[26] K. H. Orstavik, R. E. Orstavik, and M. Schwartz, “Skewed X chromosome inactivation in a female with haemophilia B and in her non-carrier daughter: a genetic influence on X chromosome inactivation?” Journal of Medical Genetics, vol. 36, no. 11, pp. 865–866, 1999.

[27] K. Okumura, Y. Fujimori, A. Takagi et al., “Skewed X chromosome inactivation in fraternal female twins results in moderately severe and mild haemophilia B,” Haemophilia, vol. 14, no. 5, pp. 1088–1093, 2008.

[28] K. Devriendt, G. Matthijs, E. Legius et al., “Simple skewed X-chromosome inactivation in a manifesting carrier of X-linked myotubular myopathy and in her non-manifesting carrier daughter: a genetic influence on X chromosome inactivation?” American Journal of Human Genetics, vol. 62, no. 3, pp. 581–587, 1997.

[29] J. R. Lupski, C. A. Garcia, H. Y. Zoghbi, E. P. Hoffman, and R. G. Fenwick, “Discordance of muscular dystrophy in monzygotic female twins: evidence supporting asymmetric splitting of the inner cell mass in a manifesting carrier of duchenne dystrophy,” American Journal of Medical Genetics, vol. 40, no. 3, pp. 354–364, 1991.

[30] S. M. Tanner, K. H. Ørstavik, M. Kristiansen et al., “Skewed X-inactivation skewing,” Nature Reviews Cancer, vol. 7, no. 8, pp. 651–658, 2007.

[31] A. D. Riggs, “In vivo footprint and methylation analysis by PCR-aided genomic sequencing: comparison of active and inactive X chromosomal DNA at the CpG island and promoter of human PGK-1,” Genes & Development, vol. 4, no. 8, pp. 1669–1677, 1990.

[32] J. B. Lawrence, “The disappearing Barr body in breast and ovarian cancers,” Nature, vol. 40, no. 8, pp. 343–349, 2000.

[33] R. Migeon and C. Haisley-Royster, “Familial skewed X inactivation and X-linked mutations: unbalanced X inactivation is a powerful means to ascertain X-linked genes that affect cell proliferation,” The American Journal of Human Genetics, vol. 62, no. 6, pp. 1555–1557, 1998.
female adolescents with autoimmune thyroid disease," *Clinical Endocrinology*, vol. 89, no. 6, pp. 863–869, 2018.

[68] G. Chabchoub, E. Uz, A. Maalej et al., “Analysis of skewed X-chromosome inactivation in females with rheumatoid arthritis and autoimmune thyroid diseases,” *Arthritis Research & Therapy*, vol. 11, no. 4, p. R106, 2009.

[69] B. Ji, K. K. Higa, J. R. Kelsoe, and X. Zhou, "Over-expression of XIST, the master gene for X chromosome inactivation, in females with major affective disorders," *EbioMedicine*, vol. 2, no. 8, pp. 909–918, 2015.

[70] S. Jaillon, K. Berthenet, and C. Garlanda, "Sexual dimorphism in innate immunity," *Clinical Reviews in Allergy & Immunology*, vol. 56, no. 3, pp. 308–321, 2019.

[71] V. R. Moulton, "Sex hormones in acquired immunity and autoimmune disease," *Frontiers in Immunology*, vol. 9, p. 2279, 2018.

[72] P. López, L. Mozo, C. Gutiérrez, and A. Suárez, "Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features," *Lupus*, vol. 12, no. 11, pp. 860–865, 2003.

[73] C. H. Feldman, L. H. Hiraki, J. Liu et al., "Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicare coverage, 2000–2004," *Arthritis and Rheumatism*, vol. 65, no. 3, pp. 753–763, 2013.

[74] Z. Zhu, Z. Liang, H. Liyan et al., "Discovery of a novel genetic susceptibility locus on X chromosome for systemic lupus erythematosus," *Arthritis Research & Therapy*, vol. 17, no. 1, p. 349, 2015.

[75] C. O. Jacob, J. Zhu, D. L. Armstrong et al., "Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus," *Proceedings of the National Academy of Sciences*, vol. 106, no. 15, pp. 6256–6261, 2009.

[76] F. Rees, M. Doherty, M. J. Grainge, P. Lanyon, and W. Zhang, "The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies," *Rheumatology*, vol. 56, no. 11, pp. 1945–1961, 2017.

[77] B. Namjou, P. H. Kothari, J. A. Kelly et al., "Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort," *Genes & Immunity*, vol. 12, no. 4, pp. 270–279, 2011.

[78] G. Hom, R. R. Graham, B. Modrek et al., "Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGA5," *New England Journal of Medicine*, vol. 358, no. 9, pp. 900–909, 2008.

[79] V. Gately, J. K. Sandling, G. Hom et al., "A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus," *Nature Genetics*, vol. 41, no. 11, pp. 1228–1233, 2009.

[80] J.-W. Han, H.-F. Zheng, Y. Cui et al., "Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus," *Nature Genetics*, vol. 41, no. 11, pp. 1234–1239, 2009.

[81] W. Stohl, J. E. Elliott, A. S. Hamilton, D. M. Deapen, T. M. Mack, and D. A. Horwitz, "Impaired recovery and cytolytic function of CD56+ T and non-T cells in systemic lupus erythematosus following in vitro polyclonal T cell stimulation. Studies in unselected patients and monoyzocytic disease-discordant twins," *Arthritis & Rheumatism*, vol. 39, no. 11, pp. 1840–1851, 1996.

[82] Q. Huang, A. Parfitt, D. M. Grennan, and N. Manolios, “X-chromosome inactivation in monoyzocytic twins with systemic lupus erythematosus,” *Autoimmunity*, vol. 26, no. 2, pp. 85–93, 1997.

[83] R. E. Kast, "Predominance of autoimmune and rheumatic diseases in females," *Journal of Rheumatology*, vol. 4, no. 3, pp. 288–292, 1977.

[84] J. J. Stewart, "The female X-inactivation mosaic in systemic lupus erythematosus," *Immunology Today*, vol. 19, no. 8, pp. 352–357, 1998.

[85] M. Kiriakidou and C. L. Ching, *Systemic Lupus Erythematosus*. *Annals of Internal Medicine*, vol. 172, no. 11, pp. Itc81–Itc96, 2020.

[86] T. Dörner and R. Furie, "Novel paradigms in systemic lupus erythematosus," *Lancet (North American Edition)*, vol. 393, no. 10188, pp. 2344–2358, 2019.

[87] S. Laffont and J.-C. Guéry, "Deconstructing the sex bias in allergy and autoimmunity: from sex hormones and beyond," *Advances in Immunology*, vol. 142, pp. 35–64, 2019.

[88] I. Sekigawa, T. Naito, K. Hira et al., "Possible mechanisms of gender bias in SLE: a new hypothesis involving a comparison of SLE with atopy," *Lupus*, vol. 13, no. 4, pp. 217–222, 2004.

[89] N. Dragin, J. Bismuth, G. Cizeron-Clairac et al., "Estrogen-mediated downregulation of AIRE influences sexual dimorphism in autoimmune diseases," *Journal of Clinical Investigation*, vol. 126, no. 4, pp. 1525–1537, 2016.

[90] M.-L. Zhu, P. Bakhru, B. Conley et al., "Sex bias in CNS autoimmune disease mediated by androgen control of autoimmunity regulator," *Nature Communications*, vol. 7, no. 1, Article ID 11350, 2016.

[91] F. Rees, M. Doherty, M. Grainge, G. Davenport, P. Lanyon, and W. Zhang, "The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012," *Annals of the Rheumatic Diseases*, vol. 75, no. 1, pp. 136–141, 2016.

[92] L. Arnaud, J.-P. Fagot, A. Mathian, M. Paita, A. Fagot-Campagna, and Z. Amoura, "Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study," *Autoimmunity Reviews*, vol. 13, no. 11, pp. 1082–1089, 2014.

[93] C. M. Cooney, G. R. Bruner, T. Aberle et al., "46, X, del (X) (q13) Turner’s syndrome women with systemic lupus erythematosus in a pedigree multiplex for SLE," *Genes & Immunity*, vol. 10, no. 5, pp. 478–481, 2009.

[94] R. H. Scofield, G. R. Bruner, B. Namjou et al., "Klinefelter’s syndrome (47, XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome," *Arthritis & Rheumatism*, vol. 58, no. 8, pp. 2511–2517, 2008.

[95] K. Liu, B. T. Kurien, S. L. Zimmerman et al., "X chromosome dose and sex bias in autoimmune diseases: increased prevalence of 47, XXX in systemic lupus erythematosus and sjögren’s syndrome," *Arthritis & Rheumatology*, vol. 68, no. 5, pp. 1290–1300, 2016.

[96] C. C. Whitacre, "Sex differences in autoimmune disease," *Nature Immunology*, vol. 2, no. 9, pp. 777–780, 2001.

[97] D. L. Smith-Bouvier, A. A. Divekar, M. Sasidhar et al., "A role for sex chromosome complement in the female bias in autoimmune disease," *Journal of Experimental Medicine*, vol. 205, no. 5, pp. 1099–1108, 2008.

[98] V. M. Harris, K. A. Koelsch, B. T. Kurien et al., "Characterization of cxsrf21 provides molecular insight into female-bias immune response in SLE pathogenesis," *Frontiers in Immunology*, vol. 10, p. 2160, 2019.

[99] A. Desai-Mehta, L. Lu, R. Ramsey-Goldman, and S. K. Datta, "Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production,"
